// App-Quantinova.ai

: Safety of Long-Term Dupilumab Treatment in Adults With Moderate-to-Severe Atopic Dermatitis: Results from an Open-Label Extension (OLE) Trial up to 4 years

Researchers

Presenter

  • Andreas Wollenberg

Principal Investigators

  • Weily Soong

  • Melinda Goooderham

  • Robert Bissonnette

  • Jing Xiao

  • Faisal A. Khokhar

  • Ainara Rodríguez Marco

  • Noah A. Levit

  • Arsalan Shabbir

Medical Centers

  • Ludwig Maximilians University Munich, Munich, Germany

  • Alabama Allergy & Asthma Center, Birmingham, AL, United States,

  • SKiN Centre for Dermatology, Peterborough, ON, Canada

  • Queen's University, Kingston, ON, CA

  • Regeneron Pharmaceuticals, Inc., Tarrytown, NY

  • Sanofi Genzyme, Madrid, Spain

Locations

  • United States

  • Canada

  • United Kingdom

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Dermatology

Disease

  • Atopic Dermatitis

Biomarkers

  • N/A

Drug/Treatment

  • Dupilumab

Outcome

  • N/A

Study Design

  • Open Label

Phase

  • N/A

Study Id's

  • NCT01949311

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved